ThromboGenics NV Announces Business Update and Half Year Re...(ad a strong cash position of EUR52.6mill...)

These funds will allow ThromboGenics to support its business for approximately the next two years. The Company's underlying cash burn is expected to increase given the continuing investment in the Phase III program for microplasmin in eye disease, as well as the start of ThromboGenics own commercial activities to ensure the successful launch of this exciting new product.

At the end of June 2009, ThromboGenics had total shareholders equity of EUR61.1 million which compares with EUR67.6 million at the end of June 2008.

ThromboGenics experienced a EUR4.6 million cash outflow in the first half of 2009. This compares with a cash outflow of EUR8.1 million in the first half of 2008, when the Company was still awaiting payment of the EUR30 million upfront payment from Roche.

    Unaudited consolidated statement of profit and loss

                                  ThromboGenics

               Unaudited consolidated statement of profit and loss

                                              Half year         Half year
    In '000 Euro, except per share amounts    6 months          6 months
              According to IFRS            Jan - June 2009   Jan - June 2008
    Income                                           3,609            30,298
                            License income           3,549            30,255
                            Royalty income              54                 -
                              Other income               6                43
    Cost of sales                                     (454)              (29)
    Gross profit                                     3,155            30,269
    Research and development expenses               (8,842)          (11,582)
    General and administrative expenses            
'/>"/>
SOURCE  ThromboGenics NV
Copyright©2009 PR Newswire.
All rights reserved

2

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 
Related biology technology :

1. ThromboGenics NV: Business Update
2. ThromboGenics Announces Business Update and 2008 Full Year Results
3. ThromboGenics and BioInvent Start Phase II Trial of TB-402, a Novel, Long Acting Anticoagulant for Deep Vein Thrombosis (DVT) Prophylaxis
4. ThromboGenics N.V.: Business Update
5. ThromboGenics Announces Half Year Results 2008
6. ThromboGenics Appoints Dr. Patrik De Haes as Chief Executive Officer
7. ThromboGenics Announces Private Investors Acquire 8% Stake in the Company
8. ThromboGenics and BioInvent Announce a Strategic Alliance With Roche for TB-403, a Novel Anti-Cancer Antibody
9. ThromboGenics N.V. - Business Update
10. ThromboGenics Completes Patient Enrolment of MITI IV Trial, a Phase II Study Evaluating the Safety and Preliminary Efficacy of Microplasmin in the Treatment of Acute Stroke
11. ThromboGenics Announces 2007 Full Year Results